Home TV News New Special ‘South Park: The End Of Obesity’ To Premiere In May On Paramount+

New Special ‘South Park: The End Of Obesity’ To Premiere In May On Paramount+

by Dave Elliott

Paramount+ UK has announced the new South Park special, ‘South Park: The End Of Obesity’, will premiere this May on the streaming service.

In ‘South Park: The End Of Obesity’, the advent of new weight loss drugs has a huge impact on everyone in South Park. When Cartman is denied access to the life-changing medicine, the kids jump into action.

The hit animated franchise South Park, which celebrated its 25th anniversary in 2022, debuted on Comedy Central August 13, 1997. Stan, Kyle, Cartman and Kenny were first seen in the animated short “The Spirit of Christmas,” and from there were launched into television history. Co-creators Trey Parker and Matt Stone are executive producers, along with Anne Garefino and Frank C. Agnone II. Eric Stough, Adrien Beard, Bruce Howell and Vernon Chatman are producers. Christopher Brion is the Creative Director of South Park Digital Studios. South Park’s website is SouthPark.cc.com.

Building on MTV Entertainment Studios’ expansive deal with co-creators Trey Parker and Matt Stone, South Park has been renewed on Comedy Central through 2027, taking cable’s longest-running scripted series through an unprecedented 30th season.

All the previous specials – ‘South Park: Post Covid’, ‘South Park: Post Covid: The Return Of Covid’, ‘South Park The Streaming Wars’, ‘South Park The Streaming Wars Part 2’, ‘South Park: Joining The Panderverse’ and the recently released ‘South Park (Not Suitable For Children)’ – are currently available to stream exclusively on Paramount+.

South Park: The End Of Obesity‘ premieres Friday, 24th May 2024 in the U.S. and Canada, and on Saturday, 25th May 2024 in the U.K., Australia, Latin America, Brazil, France, Italy, Germany, Switzerland and Austria.

You may also like

Subscribe
Notify of
guest

This site uses Akismet to reduce spam. Learn how your comment data is processed.

0 Comments
Inline Feedbacks
View all comments